"Are peptides legal?" is one of the most common questions about compounds like BPC-157, TB-500 and Semax — and the honest answer is that it depends on what you mean by legal. There is a big difference between a peptide being an FDA-approved drug, being eligible for pharmacy compounding, and being sold as a research chemical. 2026 was a pivotal year for this, so here is a plain-English explainer of where things actually stand.
The Short Answer
Most research peptides are not FDA-approved drugs. A small number are (tesamorelin, sold as Egrifta, is the clearest example). In July 2026, an FDA advisory committee recommended several popular peptides for a compounding pathway, but that recommendation is advisory, not law — it does not make those peptides approved, and it does not by itself make them legal to compound or sell for personal use.
Three Different Legal Statuses
It helps to separate three things people lump together:
-
FDA-approved drug: tested, approved for a specific use, available by prescription. Among common peptides, tesamorelin is the main one.
-
Compounded drug: made by a licensed pharmacy for a specific patient, using a substance that qualifies under section 503A. This is the pathway the 2026 vote was about.
-
Research chemical: sold "for research use only, not for human consumption." This is how most peptides are sold online, and it is a different lane from either of the above.
The 503A Bulk List and Why It Matters
For a pharmacy to legally compound a drug from a bulk substance, that substance generally has to meet one of three conditions: it has a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on the FDA's 503A bulk drug substances list. Most research peptides meet none of these, which is why compounding them has existed in a legal gray zone.
The FDA has sorted nominated substances into interim categories while it reviews them. Category 1 means the FDA has adequate support and no significant safety concern, and those substances get enforcement discretion. Category 2 means significant safety concerns were identified, and Category 3 means inadequate information — neither gets enforcement discretion. In April 2026, twelve peptides were removed from Category 2 after their nominations were withdrawn; importantly, removal from Category 2 does not automatically grant Category 1 status.
What Happened in July 2026
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) held a two-day public meeting and voted on seven peptides. It recommended six of them for the 503A bulk list:
| Peptide | PCAC vote | Recommended? |
|---|---|---|
| BPC-157 | 8–6 (1 abstention) | Yes |
| KPV | 8–6 (1 abstention) | Yes |
| TB-500 | 8–6 (1 abstention) | Yes |
| MOTS-c | 7–5 (2 abstentions) | Yes |
| Epitalon | 7–4 (1 abstention) | Yes |
| Semax | 8–5 (1 abstention) | Yes |
| Emideltide (DSIP) | 6–7 (1 abstention) | No |
Notably, the panel voted against FDA staff, who had recommended against all seven.
What the Vote Does Not Mean
This is where most online coverage overreaches. The PCAC vote:
-
Is advisory, not binding. The FDA can accept, reject or delay it.
-
Does not add anything to the 503A list yet. That requires formal notice-and-comment rulemaking — a proposed rule, a public comment period and a final rule — which could finish in 2027 or take years.
-
Does not make any peptide an approved drug. None of the seven is FDA approved.
-
Does not legalize research-chemical sales for personal use. The compounding pathway is about licensed pharmacies and specific patients, not online purchases.
Until rulemaking is complete, these peptides still do not meet the three permitted bases for 503A compounding.
Where Common Peptides Stand
-
BPC-157 and TB-500: not approved; recommended for compounding in July 2026; banned in tested sport.
-
MOTS-c: not approved; recommended for compounding in July 2026.
-
Semax: not approved in the US; recommended for compounding in July 2026; a registered medicine in Russia.
-
Selank: not approved; was not among the peptides reviewed in 2026; a registered medicine in Russia.
-
NAD+ and precursors: sold largely as supplements; regulatory treatment differs from the injectable peptides above.
-
Tesamorelin: FDA approved (Egrifta) for a specific indication; prescription only; other uses are off-label.
-
GHK-Cu: widely sold as a topical cosmetic ingredient; injectable forms are not approved and were under FDA review.
State Rules and Sport
Federal status is not the whole story. States can impose their own rules — some explicitly bar compounding of Category 2 or 3 peptides. And for athletes, many of these peptides (including growth-hormone secretagogues and GHRH analogs) are prohibited at all times under the World Anti-Doping Code, regardless of their FDA status.
Frequently Asked Questions
Are peptides legal to buy in the US?
Most research peptides are not FDA-approved drugs and are sold "for research use only, not for human consumption." That is a different legal category from approved or compounded medicines, and buying them for personal use is not the same as having a legal, approved treatment.
Did the FDA approve peptides in 2026?
No. In July 2026 an FDA advisory committee recommended six peptides for a compounding pathway, but that is advisory only. No new peptide was approved as a drug, and formal rulemaking would be required before any could be legally compounded.
Which peptides are FDA approved?
Among commonly discussed peptides, tesamorelin (Egrifta) is FDA approved for a specific indication. Most others — BPC-157, TB-500, Semax, Selank, MOTS-c — are not approved.
What is the 503A bulk list?
It is the FDA list of bulk substances that licensed pharmacies may use for compounding. A substance generally must be on that list, have a USP/NF monograph, or be part of an approved drug to be compounded legally.
Disclaimer
This article is for educational and informational purposes only and is not legal or medical advice. Regulatory status changes; verify current FDA guidance before relying on it. The Peptide Library is operated in connection with ZenoPeps. Research products are sold for research use only and are not intended for human consumption.
References
-
FDA Panel Backs 6 Peptides for Compounding, AJMC, July 2026.
-
Bulk-list bound? PCAC backs majority of peptides, McDermott, July 2026.
-
FDA: Bulk Drug Substances Used in Compounding Under Section 503A.